Proprietary Deal Flow: The Quiet Engine of Top-Tier Venture Funds
In venture, the best deals don’t knock, they whisper. Here's how top funds source them before anyone else knows they exist.
Dear Readers,
Welcome to the latest edition of the HealthVC newsletter.
After four years of decoding the language of venture capital, HealthVC is entering its next chapter.
We're no longer just interpreting the market; we're building the infrastructure for those actively shaping it.
The new HealthVC is designed for founders who are raising serious capital in healthtech, and for investors who want to raise a fund or want a sharper edge in evaluating deals across Europe and beyond. This isn’t content. It’s an operating system for navigating the capital stack more effectively.
Here’s what subscribers now receive:
A meticulously curated database of 1,000+ verified investors, updated monthly. (700 LPs and 500 Angel Investors will be added this month)
Battle-tested outreach email templates to cut through the noise
Fundable pitch deck frameworks grounded in real VC feedback
The HealthVC Fundraising Playbook process, narrative, and sequencing
Access to a monthly private Q&A, covering capital strategy, market timing, and investor engagement
A quarterly group strategy session – focused on pipeline, positioning, and portfolio alignment
Direct, personalized feedback on investor emails and pitch decks
Entry into the HealthVC WhatsApp community, a discreet network of founders and capital allocators
Advanced database filters to identify the right investor at the right stage
If you’re raising a venture fund, building a startup, or backing those who are, this is the inside track.
Subscribe now and lock in 25% off for life using this link:
👉 https://healthvc.substack.com/69ca810d
Today, we're unpacking one of the most valuable but often misunderstood levers in venture capital success: proprietary deal flow. For fund managers, this isn’t just a sourcing tactic; it’s a reflection of brand, trust, specialization, and long-term strategy. Proprietary deal flow sits at the heart of a firm’s ability to consistently outperform, not only by accessing promising companies earlier but by shaping the terms and trajectory of those partnerships.
In this issue, we take a clear-eyed look at what proprietary deal flow actually means, beyond the buzzword, and why it plays such a critical role in fund performance. We’ll explore how it’s cultivated over time, where it can go wrong, and why limited partners should pay close attention to it as a signal of a fund’s long-term viability. Whether you're an emerging manager seeking to differentiate your firm or an LP trying to identify the next standout fund, this edition dives deep into the mechanics behind high-quality, high-conviction deal sourcing.
What Proprietary Deal Flow Really Means
At its core, deal flow refers to the stream of potential investments that arrive at a fund’s doorstep. That flow can come from various sources inbound emails, demo day presentations, founder intros, or platform submissions. But most of it is what I’d call public domain deal flow, the kind that dozens of other investors also see. It’s transactional, often rushed, and typically well-polished by the time it reaches you. There’s nothing inherently wrong with it, but it’s also where the competition is fiercest and your ability to shape terms is weakest.
Proprietary deal flow is different. It represents investment opportunities that come to you directly and, crucially, exclusively, often before any formal process has begun. These are deals sourced through long-standing relationships, deep sector involvement, or trusted ecosystem signals. They come quietly via a warm intro from a former portfolio founder, a university spinout flagged by a domain expert, or a researcher you’ve been following for years who just filed their first patent.
This type of deal flow is valuable not just because it’s early or exclusive, but because it reflects a deeper form of trust. Founders are choosing to speak with you first, sometimes even before they have a pitch deck. That tells you something about the fund’s positioning not just in the market, but in the founder’s mind. And that, ultimately, is the most reliable signal of long-term advantage.
Why It Matters More Than Ever
In a funding environment where capital is increasingly commoditized, access is everything. The best founders today are not short on funding options — they’re short on trusted partners. When a fund becomes the first call a founder makes, not after a round is planned, but when an idea is just forming, the dynamic changes completely. You're not reacting to a competitive process; you're helping shape the foundation of the business. That level of proximity is incredibly powerful.
Proprietary deal flow matters because it gives funds the chance to engage earlier, assess risk more holistically, and align incentives before the momentum of the market dictates terms. You get time to run technical diligence at your own pace, have deeper strategic conversations with the team, and build conviction before there's pressure to commit.
It also opens the door to more favorable deal structures. Without multiple term sheets flying around, funds can negotiate in ways that reflect long-term partnership, not short-term FOMO. From board seats to option pool design to liquidation preferences, having a bilateral conversation, rather than a beauty contest, leads to more thoughtful structuring.
Finally, it adds diversification. Proprietary deal flow doesn’t just offer earlier access; it often leads to investments that are meaningfully different from those being pursued by other funds. That’s a huge advantage when building a portfolio. In markets like health tech, where hype cycles move fast, avoiding the herd is often the difference between real alpha and crowded mediocrity.
Not All Proprietary Deals Are Created Equal
The phrase "proprietary deal" can be seductive, but not all exclusivity is created equal. One of the most common misconceptions is that if a deal is off-market, it must be good. That’s simply not true. Some deals are proprietary because they’ve been quietly passed over by others for valid reasons — unclear IP ownership, unproven teams, or mismatched market timing.
Exclusivity can breed overconfidence. I've seen funds get emotionally attached to being “early” and let that cloud their diligence. The reality is, early access only matters if it's coupled with strong evaluation frameworks. Otherwise, you risk anchoring on the novelty of a deal rather than the fundamentals.
There’s also a danger in mistaking isolation for proprietary access. Just because a founder isn’t shopping the deal doesn’t mean they’re choosing you; they may simply not have built the network yet. This is particularly relevant with first-time founders or academic spinouts. Without rigorous vetting, the desire to be “first in” can lead to investing in deals that are simply underexposed, not overlooked because of uniqueness, but because of a lack of validation.
This is why internal filters matter. At our fund, we use a combination of domain expertise, scientific diligence, and commercial viability assessments to evaluate every proprietary deal, the same way we’d treat a competitive one. There’s no shortcut. Proprietary deal flow is only as valuable as your ability to qualify and support what you find.
How It’s Built And Earned
Proprietary deal flow doesn’t emerge overnight; it’s the result of consistent presence, long-term investment in relationships, and a clear value proposition to founders beyond capital. You don’t get invited into early conversations because of your fund size or logo. You earn that trust by showing up, adding value, and staying curious.
Sector specialization is one of the strongest drivers. When a founder sees that you understand their space on a first-principles level, the regulatory nuance, the clinical trial roadmap, and the go-to-market dynamics in healthcare, you’re immediately differentiated. You’re no longer just a capital provider; you're a strategic ally who speaks their language and understands their pain points. That’s why we’ve focused our platform on health tech and biotech: we want to be the first call for the founder who’s building at the frontier of life sciences.
We also invest in ecosystem embedding, not just attending events, but hosting founder dinners, scientific salons, and roundtable discussions with regulators and operators. These aren’t branding exercises; they’re knowledge exchanges. And they’re where real trust gets built. When a founder walks away from a session thinking, “They really get it,” they’re much more likely to come to you before they go to market.
Our scout network reflects the same philosophy. We don’t hire scouts to “source more leads.” We build long-term relationships with former founders, clinicians, and technical experts who understand our bar and share our belief in the power of early-stage science. The best deals we’ve seen came not from cold outreach, but from someone deep in the trenches who said, “You need to talk to this person, there’s something special here.”
Proactive sourcing also plays a role. Sometimes the best opportunities aren't even thinking about fundraising. A published paper, a new regulatory submission, or a stealth product launch can trigger an outbound note, not with a pitch, but with genuine curiosity. Some of our highest-conviction investments started with a single email that said: “I saw what you’re working on. Let’s talk.”
A Lens LPs Should Pay Attention To
For limited partners, proprietary deal flow is more than just a sourcing stat; it’s a window into a fund’s ecosystem position. It reveals whether a fund is integrated, respected, and trusted by the builders who matter. A fund with strong proprietary access likely has strong founder relationships, a clear strategic focus, and the kind of operational credibility that founders talk about behind closed doors.
This matters even more in European ventures, where ecosystems are smaller, more fragmented, and often built on personal connections rather than open networks. In this context, proprietary deal flow is less about hype and more about embeddedness. Is the GP regularly invited into academic labs, clinical trials, and technical founding teams before the broader market hears about them? That’s a powerful differentiator, and one that doesn’t show up in a standard pitch deck.
Especially with emerging managers, proprietary deal flow is often the best leading indicator of future outperformance. Without a decade of DPI to point to, what you can show LPs is access: who calls you, why they trust you, and what kind of opportunities you’re seeing that others aren’t. When LPs dig into that, they start to understand whether a fund is just riding the market or actively shaping it.
LPs evaluating venture funds should ask:
Where did your last five deals come from?
Were you the first call? If so, why?
What do founders say about working with you, off the record?
Those are the questions that get to the heart of whether a fund has a true edge or just good timing.
Final Thoughts
Proprietary deal flow is not about being secretive or opportunistic. It’s about earning trust at scale. It reflects a firm’s capacity to build enduring relationships, offer differentiated insight, and show up consistently in the spaces where real innovation is happening. It’s not something you can fake, and it’s not something that grows through marketing alone.
For fund managers, it’s a strategic asset that compounds. Each high-integrity relationship leads to another. Each value-added founder experience becomes part of your brand. Over time, the best opportunities find their way to you, not because you asked, but because you’ve become the obvious choice.
And for LPs, it’s one of the clearest signals of a fund’s long-term relevance. Before you ask about IRR or follow-on rates, ask how the fund is sourcing its deals, and who’s bringing them in the first place. Because by the time a great deal hits the open market, the best seats are already taken.
P.S. Want to Stay Informed: Subscribe to HealthVC Pro, The Operating System for Fundraising in Europe
Stop guessing. Start executing.
HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in venture capital today:
💥 A live, filterable database of 1,000+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging
Whether you’re raising your first round or deploying your third fund, this is your tactical edge.
Subscribe now and operate like a pro
Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.
Until next time, keep venturing forward!